2023
Comparison of Outcomes of Hematopoietic Cell Transplantation (HCT) for Asymptomatic Patients with Sickle Cell Disease (SCD) and That of Propensity Matched Symptomatic Patients Undergoing HCT
Katoch D, Nallagatla V, Krishnamurti L. Comparison of Outcomes of Hematopoietic Cell Transplantation (HCT) for Asymptomatic Patients with Sickle Cell Disease (SCD) and That of Propensity Matched Symptomatic Patients Undergoing HCT. Blood 2023, 142: 3873. DOI: 10.1182/blood-2023-190977.Peer-Reviewed Original ResearchHematopoietic cell transplantationSickle cell diseaseComplications of SCDGraft failureOverall survivalAsymptomatic patientsAvascular necrosisSCD patientsDonor typeChronic GVHDCell transplantationCell diseaseOutcomes of HCTPost-transplant lymphoproliferative disorderSubstantial short-term morbidityCommon graft sourceExperienced graft failureHCT comorbidity indexAcute chest syndromeHLA-identical donorShort-term morbidityLong-term sequelaePotential curative optionSubset of patientsOrgan-specific complications
2019
Excellent Overall Survival and Low Incidence of Late Effects in Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Sickle Cell Disease: A Report from the Center for International Blood and Marrow Transplant Research (CIBMTR)
Stenger E, Phelan R, Shaw B, Battiwalla M, Bo-Subait S, Brazauskas R, Buchbinder D, Hamilton B, Shenoy S, Krishnamurti L. Excellent Overall Survival and Low Incidence of Late Effects in Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Sickle Cell Disease: A Report from the Center for International Blood and Marrow Transplant Research (CIBMTR). Blood 2019, 134: 697. DOI: 10.1182/blood-2019-128797.Peer-Reviewed Original ResearchHematopoietic cell transplantationSickle cell diseaseAcute chest syndromeMarrow Transplant ResearchLate effectsCumulative incidenceRisk factorsChest syndromeInternational BloodAvascular necrosisMultivariable analysisUnrelated donorsPatient populationTransplant ResearchCell diseaseAllogeneic hematopoietic cell transplantMyeloablative hematopoietic cell transplantationVaso-occlusive pain crisesAllogeneic hematopoietic cell transplantationDiagnosis of SCDMultivariable Cox regression analysisFirst hematopoietic cell transplantationOlder ageExcellent overall survivalHematopoietic cell transplant
2011
Non-Cardiopulmonary Factors Affecting the Six-Minute Walk Distance in Patients with Sickle Cell Disease: Results From the Walk-PHaSST Study
Goel R, Hassell K, Machado R, Barst R, Yovetich N, Kato G, Gordeuk V, Little J, Gibbs J, Schraufnagel D, Girgis R, Rosenzweig E, Morris C, Badesch D, Lanzkron S, Onyekwere O, Nouraie M, Castro O, Sachdev V, Waclawiw M, Woolson R, Goldsmith J, Gladwin M, Krishnamurti L. Non-Cardiopulmonary Factors Affecting the Six-Minute Walk Distance in Patients with Sickle Cell Disease: Results From the Walk-PHaSST Study. Blood 2011, 118: 1074. DOI: 10.1182/blood.v118.21.1074.1074.Peer-Reviewed Original ResearchTR jet velocitySickle cell diseaseSix-minute walk distanceAvascular necrosisMultivariable linear regressionPulmonary hypertensionCell diseasePrimary endpointWalk distanceChronic painSCD patientsSevere genotypeAmerican Thoracic Society guidelinesSix-minute walk testSelf-reported medical historyThoracic Society guidelinesMulti-center studySided p valueGreater predictive valueCardiopulmonary factorsOral sildenafilPain 2NT-proBNPExercise capacityWalk test